Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclidinium Bromide Efficacy and Safety in Moderate to Severe COPD
NCT00891462Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2009
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of aclidinium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change From Baseline in Morning Pre-dose Forced Expiratory Volume in 1 Second (FEV1) at 12 weeks. Started Apr 2009; status: completed.
02
Drugs
aclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00891462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00891462.